How to buy Kura Oncology stock

Kura Oncology, Inc is a biotechnology business based in the US. Kura Oncology shares (KURA) are listed on the NASDAQ and all prices are listed in US Dollars. Kura Oncology employs 71 staff and has a market cap (total outstanding shares value) of USD$1.9 billion.

How to buy shares in Kura Oncology

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Kura Oncology. Find the stock by name or ticker symbol: KURA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kura Oncology reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kura Oncology, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Kura Oncology. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Kura Oncology share price

Use our graph to track the performance of KURA stocks over time.

Kura Oncology shares at a glance

• Key figures

Information last updated 2020-10-20.

52-week range	USD$6.35 - USD$35.25
50-day moving average	USD$29.5823
200-day moving average	USD$19.7796
Wall St. target price	USD$30.5
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.568

Buy Kura Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Kura Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Kura Oncology, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kura Oncology financials

Gross profit TTM	USD$0
Return on assets TTM	-15.76%
Return on equity TTM	-26%
Profit margin	0%
Book value	$5.735
Market capitalisation	USD$1.9 billion

TTM: trailing 12 months

Shorting Kura Oncology shares

There are currently 3.0 million Kura Oncology shares held short by investors – that's known as Kura Oncology's "short interest". This figure is 22.6% down from 3.9 million last month.

There are a few different ways that this level of interest in shorting Kura Oncology shares can be evaluated.

Kura Oncology's "short interest ratio" (SIR)

Kura Oncology's "short interest ratio" (SIR) is the quantity of Kura Oncology shares currently shorted divided by the average quantity of Kura Oncology shares traded daily (recently around 772082.73195876). Kura Oncology's SIR currently stands at 3.88. In other words for every 100,000 Kura Oncology shares traded daily on the market, roughly 3880 shares are currently held short.

However Kura Oncology's short interest can also be evaluated against the total number of Kura Oncology shares, or, against the total number of tradable Kura Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kura Oncology's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Kura Oncology shares in existence, roughly 50 shares are currently held short) or 0.0636% of the tradable shares (for every 100,000 tradable Kura Oncology shares, roughly 64 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kura Oncology.

Find out more about how you can short Kura Oncology stock.

Kura Oncology share dividends

We're not expecting Kura Oncology to pay a dividend over the next 12 months.

Kura Oncology share price volatility

Over the last 12 months, Kura Oncology's shares have ranged in value from as little as $6.35 up to $35.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kura Oncology's is 2.2885. This would suggest that Kura Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Kura Oncology overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Frequently asked questions

• What percentage of Kura Oncology is owned by insiders or institutions?

  Currently 13.022% of Kura Oncology shares are held by insiders and 73.714% by institutions.

• How many people work for Kura Oncology?

  Latest data suggests 71 work at Kura Oncology.

• When does the fiscal year end for Kura Oncology?

  Kura Oncology's fiscal year ends in December.

• Where is Kura Oncology based?

  Kura Oncology's address is: 3033 Science Park Road, San Diego, CA, United States, 92121

• What is Kura Oncology's ISIN number?

  Kura Oncology's international securities identification number is: US50127T1097

• What is Kura Oncology's CUSIP number?

  Kura Oncology's Committee on Uniform Securities Identification Procedures number is: 50127T109